blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2678327

EP2678327 - HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.06.2017
Database last updated on 14.09.2024
Most recent event   Tooltip23.06.2017No opposition filed within time limitpublished on 26.07.2017  [2017/30]
Applicant(s)For all designated states
Lupin Limited
Kalpataru Inspire
3rd Floor
Off Western Express Highway
Santacruz (East)
Mumbai 400 055 / IN
[2017/08]
Former [2016/35]For all designated states
Lupin Limited
Kalpataru Inspire
3rd Floor, Off Western Express Highway
Santacruz (East)
Mumbai 400055 / IN
Former [2014/01]For all designated states
Lupin Limited
159 CST Road
Kalina
Santacruz (East)
State of Maharashtra, Mumbai 400 098 / IN
Inventor(s)01 / SINHA, Neelima
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
02 / JANA, Gourhari
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
03 / SACHCHIDANAND, Sachchidanand
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
04 / KURHADE, Sanjay, Pralhad
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
05 / KARCHE, Navnath, Popat
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
06 / HAJARE, Anil, Kashiram
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
07 / TILEKAR, Ajay, Ramchandra
Lupin Limited (Research Park)
46A/47A Village Nande
Taluka Mulshi
Maharashtra
Pune 411 042 / IN
08 / PALLE, Venkata, P.
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
09 / KAMBOJ, Rajender, Kumar
Lupin Limited (Research Park)
46A/47A
Village Nande
Taluka Mulshi, Maharashtra
Pune 411 042 / IN
 [2014/01]
Representative(s)Watson, Robert James, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2016/33]
Former [2014/01]Watson, Robert James, et al
Mewburn Ellis LLP
33 Gutter Lane
London
EC2V 8AS / GB
Application number, filing date12709965.322.02.2012
[2016/33]
WO2012IB50806
Priority number, dateIN2011KOL24223.02.2011         Original published format: IN 242KO2011
IN2011KOL118409.09.2011         Original published format: IN 1184KO2011
[2017/16]
Former [2014/01]IN2011KOL024223.02.2011
IN2011KOL118409.09.2011
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012114285
Date:30.08.2012
Language:EN
[2012/35]
Type: A1 Application with search report 
No.:EP2678327
Date:01.01.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 30.08.2012 takes the place of the publication of the European patent application.
[2014/01]
Type: B1 Patent specification 
No.:EP2678327
Date:17.08.2016
Language:EN
[2016/33]
Type: B8 Corrected title page of specification 
No.:EP2678327
Date:28.09.2016
[2016/39]
Type: B9 Corrected patent specification 
No.:EP2678327
Date:28.12.2016
[2016/52]
Search report(s)International search report - published on:EP30.08.2012
ClassificationIPC:C07D333/22, C07D409/04, A61K31/381, A61P25/28
[2014/01]
CPC:
A61K31/5377 (EP,US); C07D333/22 (EP,KR,US); A61K31/341 (EP,US);
A61K31/381 (EP,KR,US); A61K31/40 (EP,US); A61K31/404 (EP,US);
A61K31/4436 (EP,US); A61K31/4535 (EP,US); A61K31/496 (EP,US);
A61K45/06 (EP,US); A61P1/02 (EP); A61P1/04 (EP);
A61P1/18 (EP); A61P17/06 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P25/04 (EP); A61P25/14 (EP);
A61P25/16 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P25/34 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P7/00 (EP);
C07D207/32 (EP,US); C07D207/333 (EP,US); C07D207/337 (EP,US);
C07D307/68 (EP,US); C07D333/26 (EP,US); C07D333/36 (EP,US);
C07D333/38 (EP,US); C07D409/04 (EP,KR,US) (-)
C-Set:
A61K31/381, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/01]
Extension statesBA23.09.2013
ME23.09.2013
TitleGerman:HETEROARYLDERIVATE ALS ALPHA7-NACHR-MODULATOREN[2014/01]
English:HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS[2014/01]
French:DÉRIVÉS HÉTÉROARYLE À TITRE DE MODULATEURS DES NACHR ALPHA 7[2014/01]
Entry into regional phase23.09.2013National basic fee paid 
23.09.2013Designation fee(s) paid 
23.09.2013Examination fee paid 
Examination procedure21.12.2012Request for preliminary examination filed
International Preliminary Examining Authority: EP
23.09.2013Amendment by applicant (claims and/or description)
23.09.2013Examination requested  [2014/01]
08.10.2015Despatch of a communication from the examining division (Time limit: M04)
29.01.2016Reply to a communication from the examining division
31.03.2016Communication of intention to grant the patent
30.06.2016Fee for grant paid
30.06.2016Fee for publishing/printing paid
30.06.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.10.2015
Opposition(s)18.05.2017No opposition filed within time limit [2017/30]
Fees paidRenewal fee
24.02.2014Renewal fee patent year 03
24.02.2015Renewal fee patent year 04
24.02.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipPT19.12.2016
[2017/13]
Cited inInternational search[XD]WO2008002974  (ABBOTT LAB [US], et al) [XD] 1-28 * Abstract; page 26, lines 21-27; claims; examples. *;
 [X]  - TATSUMI ET AL., "(+)-3-[2-(benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]oct ane as potent agonists for the alpha-7 nicotinic acetylcholine receptor", BIOORG. MED. CHEM. LETT., (20040101), vol. 14, no. 14, doi:10.1016/J.BMCL.2004.04.091, ISSN 0960-894X, pages 3781 - 3784, XP002327499 [X] 1-28 * Abstract; page 3783, compounds in tables 2 and 3. *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2004.04.091
 [X]  - TATSUMI ET AL., "(R)-3'-(3-Methylbenzo(b)thiophen-5-yl)- spiro(1-azabicyclo(2,2,2)octa ne-3,5'- oxazolidin)-2'-one, a Novel and Potent alpha7 Nicotinic Acetylcholine Receptor Partial Agonist Displays Cognitive Enhancing Properties", J. MED. CHEM., vol. 49, no. 14, doi:10.1021/JM060249C, ISSN 0022-2623, (20060101), pages 4374 - 4383, (20060616), XP002538696 [X] 1-28 * Abstract; page 4378, compounds in tables 1 and 2. *

DOI:   http://dx.doi.org/10.1021/JM060249C
by applicantUS4235871
 US4501728
 US4837028
 US5019369
 US5608082
 EP1012142
 US2003236413
 WO2004000792
 EP1489077
 WO2005030715
 WO2005105789
 US2006142349
 US2006258670
 WO2007031440
 EP1790640
 US2007142450
 WO2007092751
 EP1866314
 WO2009043780
 WO2009043784
 WO2009115547
 US2009253691
 WO2009127678
 WO2009127679
 WO2009135944
 WO2009145996
 US7683084
 US7741364
 US2010190819
 US2010222398
 US2010227869
 US2010240707
 WO2010130768
 WO2011036167
 WO2011064288
    - PATERSON D ET AL., PROG. NEUROBIOL., (2000), vol. 61, pages 75 - 111
    - RUBBOLI F ET AL., NEUROCHEM. INT., (1994), vol. 25, pages 69 - 71
    - ALKONDON M ET AL., EUR. J. PHARMACOL., (2000), vol. 393, pages 59 - 67
    - DAJAS-BAILADOR F ET AL., TRENDS PHARMACOL. SCI., (2004), vol. 25, pages 317 - 324
    - BITNER RS ET AL., J. NEUROSCI., (2007), vol. 27, pages 10578 - 10587
    - MCKAY BE ET AL., BIOCHEM. PHARMACOL., (2007), vol. 74, pages 1120 - 1133
    - MANSVELDER HD ET AL., PSYCHOPHARMACOLOGY (BERL, (2006), vol. 184, pages 292 - 305
    - CHAN WK ET AL., NEUROPHARMACOLOGY, (2007), vol. 52, pages 1641 - 1649
    - YOUNG JW ET AL., EUR. NEUROPSYCHOPHARMACOL., (2007), vol. 17, pages 145 - 155
    - FREEDMAN R ET AL., BIOL. PSYCHIATRY, (1995), vol. 38, pages 22 - 33
    - TSUANG DW ET AL., AM. J. MED. GENET., (2001), vol. 105, pages 662 - 668
    - CURZON P ET AL., NEUROSCI. LETT., (2006), vol. 410, pages 15 - 19
    - YOUNG JW ET AL., NEUROPSYCHOPHARMACOLOGY, (2004), vol. 29, pages 891 - 900
    - HASHIMOTO K ET AL., BIOL. PSYCHIATRY, (2008), vol. 63, pages 92 - 97
    - CARSON R ET AL., "Neuromolecular", MED., (2008), vol. 10, pages 377 - 384
    - LEONARD S ET AL., PHARMACOL. BIOCHEM. BEHAV., (2001), vol. 70, pages 561 - 570
    - FREEDMAN R ET AL., CURR. PSYCHIATRY REP., (2003), vol. 5, pages 155 - 161
    - CANNON TD ET AL., CURR. OPIN. PSYCHIATRY, (2005), vol. 18, pages 135 - 140
    - LEISER SC ET AL., PHARMACOL. THER., (2009), vol. 122, pages 302 - 311
    - SUEMARU K ET AL., NIPPON YAKURIGAKU ZASSHI, (2002), vol. 119, pages 295 - 300
    - NIZRI E ET AL., DRUG NEWS PERSPECT., (2007), vol. 20, pages 421 - 429
    - WANG HY ET AL., J. NEUROSCI., (2009), vol. 29, pages 10961 - 10973
    - FEHER A ET AL., DEMENT. GERIATR. COGN. DISORD., (2009), vol. 28, pages 56 - 62
    - NAGELE RG ET AL., NEUROSCIENCE, (2002), vol. 110, pages 199 - 211
    - JEYARASASINGAM G ET AL., NEUROSCIENCE, (2002), vol. 109, pages 275 - 285
    - MARRERO MB ET AL., BRAIN. RES., (2009), vol. 1256, pages 1 - 7
    - KUZMIN A ET AL., PSYCHOPHARMACOLOGY (BERL, (2009), vol. 203, pages 99 - 108
    - WEISS RB ET AL., PLOS GENET., (2008), vol. 4, page EL000125
    - SOLINAS M ET AL., J. NEUROSCI., (2007), vol. 27, pages 5615 - 5620
    - EBBERT JO ET AL., PATIENT. PREFER. ADHERENCE, (2010), vol. 4, pages 355 - 362
    - DECKER MW ET AL., EXPERT. OPIN. INVESTIG. DRUGS, (2001), vol. 10, pages 1819 - 1830
    - ROWBOTHAM MC ET AL., PAIN, (2009), vol. 146, pages 245 - 252
    - DAMAJ MI ET AL., NEUROPHARMACOLOGY, (2000), vol. 39, pages 2785 - 2791
    - GALLOWITSCH-PUERTA M ET AL., LIFE SCI., (2007), vol. 80, pages 2325 - 2329
    - ROSAS-BALLINA M ET AL., MOL. MED., (2009), vol. 15, pages 195 - 202
    - ROSAS-BALLINA M ET AL., J. INTERN. MED., (2009), vol. 265, pages 663 - 679
    - WESTMAN M ET AL., SCAND. J. IMMUNOL., (2009), vol. 70, pages 136 - 140
    - LIU C ET AL., CRIT. CARE. MED., (2009), vol. 37, pages 634 - 641
    - ARIAS HR ET AL., INT. J. BIOCHEM. CELL. BIOL., (2009), vol. 41, pages 1441 - 1451
    - HEESCHEN C ET AL., J. CLIN. INVEST., (2002), vol. 110, pages 527 - 536
    - CALLEJA-MACIAS IE ET AL., INT. J. CANCER., (2009), vol. 124, pages 1090 - 1096
    - SCHULLER HM ET AL., EUR. J. PHARMACOL., (2000), vol. 393, pages 265 - 277
    - OLINCY A ET AL., BIOL. PSYCHIATRY, (2005), vol. 57, no. 8
    - OLINCY A ET AL., ARCH. GEN. PSYCHIATRY, (2006), vol. 63, pages 630 - 638
    - GOLDSTEIN R ET AL., ACAD. EMERG. MED., (2007), vol. 14, no. 15
    - O'DONNELL CJ ET AL., J. MED. CHEM., (2010), vol. 53, pages 1222 - 1237
    - REDROBE JP ET AL., EUR. J. PHARMACOL., (2009), vol. 602, pages 58 - 65
    - DUNLOP J ET AL., J. PHARMACOL. EXP. THER., (2009), vol. 328, pages 766 - 776
    - PICHAT P ET AL., NEUROPSYCHOPHARMACOLOGY, (2007), vol. 32, pages 17 - 34
    - RONCARATI R ET AL., J. PHARMACOL. EXP. THER., (2009), vol. 329, pages 459 - 468
    - VAN KM ET AL., PSYCHOPHARMACOLOGY (BERL, (2004), vol. 172, pages 375 - 383
    - BOESS FG ET AL., J. PHARMACOL. EXP. THER., (2007), vol. 321, pages 716 - 725
    - HAUSER TA ET AL., BIOCHEM. PHARMACOL., (2009), vol. 78, pages 803 - 812
    - ALBUQUERQUE EX ET AL., ALZHEIMER DIS. ASSOC. DISORD., (2001), vol. 15, no. 1, pages S19 - S25
    - FAGHIH R ET AL., J. MED. CHEM., (2009), vol. 52, pages 3377 - 3384
    - NG HJ ET AL., PROC. NATL. ACAD. SCI., U. S. A., (2007), vol. 104, pages 8059 - 8064
    - TIMMERMANN DB ET AL., J. PHARMACOL. EXP. THER., (2007), vol. 323, pages 294 - 307
    - J. MED. CHEM., (2009), vol. 52, page 3377
    - TETRAHEDRON LETTERS, (2005), vol. 46, no. 43, pages 7295 - 7298
    - TETRAHEDRON LETTERS, (2003), vol. 44, no. 16, pages 3385 - 3386
    - SYNTHETIC COMMUNICATIONS, (2009), vol. 39, no. 12, pages 2082 - 2092
    - TETRAHEDRON LETTERS, (2010), vol. 51, no. 15, pages 2048 - 2051
    - TETRAHEDRON LETTERS, (2008), vol. 49, no. 18, pages 2882 - 2885
    - J. AMER. CHEM. SOC., (2005), vol. 127, no. 36, pages 12640 - 12646
    - N. MIYAURA; A. SUZUKI, CHEM. REV., (1995), vol. 95, page 2547
    - J. CHEM. SOC. PERKIN TRANS.: ORGANIC AND BIOORGANIC CHEMISTRY (1972-1999, (1972), pages 1766 - 1770
    - TETRAHEDRON, (2004), vol. 60, pages 3439 - 43
    - BIOORGANIC CHEMISTRY, (1994), vol. 22, pages 387 - 394
    - TETRAHEDRON LETTERS, (2005), vol. 46, pages 4539 - 4542
    - TETRAHEDRON LETTERS, (2010), vol. 51, pages 1693 - 1695
    - J. ORG. CHEM., (2009), vol. 74, no. 2, pages 903 - 905
    - ORGANIC LETTERS, (2007), vol. 9, no. 25, pages 5191 - 5194
    - TETRAHEDRON, (2006), vol. 62, pages 8243 - 8255
    - SYNLETT, (2002), vol. 7, pages 1152 - 1154
    - N.MIYAURA; A. SUZUKI, CHEM. REV., (1995), vol. 95, page 2547
    - ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, (2002), vol. 37, no. 5, pages 545 - 549
    - BERGE S.M. ET AL., "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1990), page 1445
    - JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, pages 2 - 19
    - THOMSEN MS ET AL., CURR. PHARM. DES., (2010), vol. 16, pages 323 - 343
    - PENG ZZ ET AL., ZHONGHUA YI XUE YI CHUAN XUE ZA ZHI, (2008), vol. 25, pages 154 - 158
    - MARTIN LF ET AL., AM. J. MED. GENET., B NEUROPSYCHIATR. GENET., (2007), vol. 144B, pages 611 - 614
    - MARTIN LF ET AL., PSYCHOPHARMACOLOGY (BERL, (2004), vol. 174, pages 54 - 64
    - WILENS TE ET AL., BIOCHEM. PHARMACOL., (2007), vol. 74, pages 1212 - 1223
    - VERBOIS SL ET AL., NEUROPHARMACOLOGY, (2003), vol. 44, pages 224 - 233
    - SANBERG PR ET AL., PHARMACOL. THER., (1997), vol. 74, pages 21 - 25
    - BENNOUNA M ET AL., ENCEPHALE, (2007), vol. 33, pages 616 - 620
    - NORDBERG A ET AL., NEUROTOX. RES., (2000), vol. 2, pages 157 - 165
    - HAYDAR SN ET AL., BIOORG. MED. CHEM., (2009), vol. 17, pages 5247 - 5258
    - DEUTSCH SI ET AL., CLIN. NEUROPHARMACOL., (2003), vol. 26, pages 277 - 283
    - ZHAO X ET AL., ANN. N. Y. ACAD. SCI., (2001), vol. 939, pages 179 - 186
    - PERRY E ET AL., EUR. J. PHARMACOL., (2000), vol. 393, pages 215 - 222
    - HARRINGTON CR ET AL., DEMENTIA, (1994), vol. 5, pages 215 - 228
    - WANG J ET AL., J. NEUROSCI. RES., (2010), vol. 88, pages 807 - 815
    - DURIS K ET AL., STROKE, (2011), vol. 42, no. 12, pages 3530 - 6
    - DONNELLY-ROBERTS DL ET AL., J. PHARMACOL. EXP. THER., (1998), vol. 285, pages 777 - 786
    - ROWLEY TJ ET AL., BR. J. ANAESTH., (2010), vol. 105, pages 201 - 207
    - BRUCHFELD A ET AL., J. INTERN. MED., (2010), vol. 268, pages 94 - 101
    - GIEBELEN IA T ET AL., SHOCK, (2007), vol. 27, pages 443 - 447
    - PENA G ET AL., EUR. J. IMMUNOL., (2010), vol. 40, pages 2580 - 2589
    - Pharmaceutics and Pharmacy Practice, J.B. LIPPINCOTT COMPANY, (1982), pages 238 - 250
    - TOISSEL, ASHP Handbook on Injectable Drugs, (1986), pages 622 - 630
    - SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., (1980), vol. 9, page 467
    - WASSERMAN ET AL., CANCER, (1975), vol. 36, pages 1258 - 1268
    - J. CHEM. SOC. PERKIN TRANS-L:0RGANIC AND BIOORGANIC CHEMISTRY, (1972), pages 1766 - 1770
    - JCS PERKIN TRANS-I:ORGANIC AND BIOORGANIC CHEMISTRY (1972-1999, (1972), pages 1766 - 1770
    - ORG. LETT., (2007), vol. 9, no. 25, pages 5191 - 5194
    - TETRAHEDRON, (2006), vol. 62, pages 7902 - 7910
    - J. ORG. CHEM., (2010), vol. 75, pages 3855 - 3858
    - FAGHIH R. ET AL., J. MED. CHEM., (2009), vol. 52, pages 3377 - 84
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.